株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

抗がん治療向けチェックポイント阻害薬の世界市場の予測:2019年~2029年

Checkpoint Inhibitors for Anti-Cancer Treatment Market 2019-2029: CTLA-4 Inhibitors, PD-1 Inhibitors, 3 PD-L1 Inhibitors, Ipilimumab, Nivolumab, Pembrolizumab, Pipeline Drugs

発行 Visiongain Ltd 商品コード 346762
出版日 ページ情報 英文 152 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=137.32円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[詳細]アイコンをクリックしてご確認ください。

抗がん治療向けチェックポイント阻害薬の世界市場の予測:2019年~2029年 Checkpoint Inhibitors for Anti-Cancer Treatment Market 2019-2029: CTLA-4 Inhibitors, PD-1 Inhibitors, 3 PD-L1 Inhibitors, Ipilimumab, Nivolumab, Pembrolizumab, Pipeline Drugs
出版日: 2019年05月28日 ページ情報: 英文 152 Pages
担当者のコメント
2018年秋の本庶佑氏ノーベル医学生理学賞で注目の的となっている免疫チェックポイント阻害剤のレポートです。今後10.年間の市場動向についての予測を記載します。
概要

世界の抗がん治療向けチェックポイント阻害薬市場は、2018年に114億3000万米ドルに達し、2029年までのCAGR (複合年間成長率) で、13.7%の成長が予測されています。

当レポートでは、世界の抗がん治療向けチェックポイント阻害薬市場について調査分析し、市場概要、市場分析・予測、地域・国別の市場機会、パイプライン分析、主要企業などについて、体系的な情報を提供しています。

第1章 レポート概要

第2章 世界の抗がん治療向けチェックポイント阻害薬市場のイントロダクション

  • 免疫療法の新時代
  • オンコロジー治療におけるチェックポイント阻害薬
  • 適応セグメント

第3章 抗がん治療向けチェックポイント阻害薬市場の主要薬の予測、世界の主要企業

  • 主要薬
    • Yervoy (イピリムマブ) :Bristol-Myers Squibb
    • Opdivo (ニボルマブ) :Bristol-Myers Squibb/小野薬品工業
    • Keytruda (ペンブロリズマブ) :Merck & Co.
  • 主要企業
    • Bristol-Myers Squibbが市場を先導

第4章 抗がん治療向けチェックポイント阻害薬:世界市場

  • 世界市場
  • 収益予測
  • 主要な二次市場予測

第5章 抗がん治療向けチェックポイント阻害薬市場の主要国市場

  • 疫学
  • 地域の内訳
  • 地域別予測
  • 米国
  • 欧州市場
  • EU
  • 日本
  • アジア太平洋地域

第6章 抗がん治療向けチェックポイント阻害薬市場のパイプライン分析

  • 抗PD-1阻害薬と抗PD-L1阻害薬
  • CTLA-4阻害薬
  • LAG-3 (リンパ球活性化遺伝子3) 阻害薬
  • KIR阻害薬
  • 抗NKG2A阻害薬
  • その他のチェックポイント阻害薬、など

第7章 抗がん治療向けチェックポイント阻害薬市場の定性分析

  • SWOT分析

第8章 企業プロファイル

  • AstraZeneca Plc.
  • Bristol-Myers Squibb Co.
  • Celldex Therapeutics Inc.
  • Incyte Corporation
  • Merck & Co., Inc.
  • Novartis Ag
  • Pfizer Inc.
  • Roche Holding Ag

第9章 結論

図表

List of Tables

  • Table 2.1 Main Types of Checkpoint Inhibitors in Development, 2018
  • Table 3.1 Yervoy (Ipilimumab): Historical Sales ($bn, AGR%), 2015-2018
  • Table 3.2 Yervoy Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2018-2024
  • Table 3.3 Yervoy Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2024-2029
  • Table 3.4 Opdivo Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2019-2024
  • Table 3.5 Opdivo Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2025-2029
  • Table 3.6 Keytruda Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2018-2024
  • Table 3.7 Keytruda Forecast, Revenue ($bn), Annual Growth (%), CAGR (%),2024-2029
  • Table 3.8 Leading Companies in the Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Revenue ($bn), Market Share (%), 2018
  • Table 4.1 Global Market for Checkpoint Inhibitor Anti-Cancer Treatment Drugs: Revenues ($bn) and Market Shares (%) by Class, 2018
  • Table 4.2 Checkpoint Inhibitors by Revenue ($bn), 2018
  • Table 4.3 Checkpoint Inhibitors by Revenue ($bn), 2018
  • Table 4.4 Global Market Forecast for Checkpoint Inhibitors Anti-Cancer Treatment Drugs by Class: Market Sizes ($bn), Annual Growth Rates (%), CAGR (%), 2018-2024
  • Table 4.5 Global Market Forecast for Checkpoint Inhibitors Anti-Cancer Treatment Drugs by Class: Market Sizes ($bn), Annual Growth Rates (%), CAGR (%), 2024-2029
  • Table 4.6 Global Market for Checkpoint Inhibitors Anti-Cancer Treatment Drugs: Revenues ($bn) and Market Shares (%) by Class, 2018
  • Table 4.7 Global Market Forecast for CTLA-4 Inhibitors: Revenue ($bn), Annual Growth Rate (%), CAGR (%), 2018-2024
  • Table 4.8 Global Market Forecast for CTLA-4 Inhibitors: Revenue ($bn), Annual Growth Rate (%), CAGR (%), 2024-2029
  • Table 4.9 Global Market Forecast for PD-1 Inhibitors: Revenue ($bn), Annual Growth Rate (%), CAGR (%), 2018-2024
  • Table 4.10 Global Market Forecast for PD-1 Inhibitors: Revenue ($bn), Annual Growth Rate (%), CAGR (%), 2024-2029
  • Table 4.11 Global Market Forecast for Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market by Class: Market Shares (%), 2018-2024
  • Table 4.12 Global Market Forecast for Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market by Class: Market Shares (%), 2024-2029
  • Table 5.1 Regional and National Breakdown of the Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Sizes ($bn), Market Shares (%), 2018
  • Table 5.2 Forecast of Regional and National Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Sizes ($bn), Annual Growth (%), CAGRs (%), 2018-2024
  • Table 5.3 Forecast of Regional and National Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Sizes ($bn), Annual Growth (%), CAGRs (%), 2024-2029
  • Table 5.4 Forecast of Regional and National Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Shares (%), 2018-2024
  • Table 5.5 Forecast of Regional and National Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Shares (%), 2024-2029
  • Table 5.6 Forecast of the US Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2018-2024
  • Table 5.7 Forecast of the US Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2024-2029
  • Table 5.8 EU Market Shares (%), 2018-2024
  • Table 5.9 EU Market Shares (%), 2024-2029
  • Table 5.10 Forecast of the EU Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2018-2024
  • Table 5.11 Forecast of the EU Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2024-2029
  • Table 5.12 Forecast of the German Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2018-2024
  • Table 5.13 Forecast of the German Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2024-2029
  • Table 5.14 Forecast of the French Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2018-2024
  • Table 5.15 Forecast of the French Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2024-2029
  • Table 5.16 Forecast of the Italian Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2018-2024
  • Table 5.17 Forecast of the Italian Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2024-2029
  • Table 5.18 Forecast of the UK Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2018-2024
  • Table 5.19 Forecast of the UK Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2024-2029
  • Table 5.20 Forecast of the Spanish Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2018-2024
  • Table 5.21 Forecast of the Spanish Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2024-2029
  • Table 5.22 Forecast of the Japanese Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2018-2024
  • Table 5.23 Forecast of the Japanese Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2024-2029
  • Table 5.24 Forecast of the APAC Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2018-2024
  • Table 5.25 Forecast of the APAC Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2024-2029
  • Table 6.1 Selected Combination Therapies for Atezolizumab, 2018
  • Table 6.2 Tecentriq Forecast: Revenue ($bn), 2018-2024
  • Table 6.3 Tecentriq Forecast: Revenue ($bn), 2024-2029
  • Table 6.4 Libtayo Forecast: Revenue ($bn), 2018-2024
  • Table 6.5 Tremelimumab Forecast: Revenue ($bn), 2018-2024
  • Table 6.6 Tremelimumab Forecast: Revenue ($bn), 2024-2029
  • Table 7.1 Strengths and Weaknesses of the Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market, 2018
  • Table 7.2 Opportunities and Threats of the Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market, 2018
  • Table 8.1 AstraZeneca PLC. Profile 2018
  • Table 8.2: AstraZeneca: Key Developments
  • Table 8.3 Bristol-Myers Squibb Co. Profile 2018
  • Table 8.4: Bristol-Myers Squibb: Key Developments
  • Table 8.5 Celldex Therapeutics Inc. Profile 2018
  • Table 8.6: Celldex Therapeutics: Key Developments
  • Table 8.7 Incyte Corporation Profile 2018 (
  • Table 8.8: Incyte: Key Developments
  • Table 8.9 Merck & Co., Inc. Profile 2018
  • Table 8.10: Merck & Co.: Key Developments
  • Table 8.11 Novartis AG Profile 2018
  • Table 8.12: Novartis: Key Developments
  • Table 8.13 Pfizer Inc. Profile 2018 (
  • Table 8.14: Pfizer: Key Developments
  • Table 8.15: Roche Holding AG Profile 2018 (
  • Table 8.16: Roche: Key Developments
  • Table 9.1 Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market Forecast by Region: Market Size ($bn), Market Share (%), CAGR (%), 2018, 2020, 2024, and 2029
  • Table 9.2 Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market Forecasts by Class: Market Size ($bn) Market Share (%), CAGR (%), 2018, 2020, 2024, and 2029

List of Figures

  • Figure 1.1 Global Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market Segmentation Overview, 2019
  • Figure 3.1 Yervoy (ipilimumab): Historical Sales ($bn), 2015-2018
  • Figure 3.2 Yervoy Forecast, Revenue ($bn), 2018-2029
  • Figure 3.3 Opdivo Forecast, Revenue ($bn), 2018-2029
  • Figure 3.4 Keytruda Forecast, Revenue ($bn), 2018-2029
  • Figure 3.5 Leading Companies in the Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market by Revenue: Market Shares, 2018 (%)
  • Figure 4.1 Global Market for Checkpoint Inhibitor Anti-Cancer Treatment Drugs: Market Shares by Class (%), 2018
  • Figure 4.2 Global Market Forecast for Checkpoint Inhibitors Anti-Cancer Treatment Drugs by Class: Market Sizes ($bn), 2018-2029
  • Figure 4.3 Global Market for Checkpoint Inhibitors Anti-Cancer Treatment Drugs: Market Shares by Class (%), 2018
  • Figure 4.4 Global Market Forecast for CTLA-4 Inhibitors: Revenue ($bn), 2018-2029
  • Figure 4.5 Global Market Forecast for PD-1 Inhibitors: Revenue ($bn), 2018-2029
  • Figure 4.6 Global Market for Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Shares by Class (%), 2024
  • Figure 4.7 Global Market for Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Shares by Class (%), 2029
  • Figure 5.1 Regional and National Breakdown of the Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Shares (%), 2018
  • Figure 5.2 Forecast of Regional and National Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Sizes ($bn), 2018-2029
  • Figure 5.3 Forecast of Regional and National Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Shares (%), 2024
  • Figure 5.4 Forecast of Regional and National Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Shares (%), 2029
  • Figure 5.5 Forecast of the US Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), 2018-2029
  • Figure 5.6 Forecast of the EU Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), 2018-2029
  • Figure 5.7 EU Market for the Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market, by Leading Country (%), 2018
  • Figure 5.8 Forecast of the EU Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market, Market Sizes ($bn), 2018-2029
  • Figure 5.9 Forecast of the German Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), 2018-2029
  • Figure 5.10 Forecast of the French Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), 2018-2029
  • Figure 5.11 Forecast of the Italian Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), 2018-2029
  • Figure 5.12 Forecast of the UK Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), 2018-2029
  • Figure 5.13 Forecast of the Spanish Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), 2018-2029
  • Figure 5.14 Forecast of the Japanese Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), 2018-2029
  • Figure 5.15 Forecast of the APAC Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Market Size ($bn), 2018-2029
  • Figure 6.1 Tecentriq Forecast: Revenue ($bn), 2018-2029
  • Figure 6.2 Tremelimumab Forecast: Revenue ($bn), 2018-2029
  • Figure 9.1 Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market Forecast by Class: Market Sizes ($bn), 2018-2029
  • Figure 9.2 Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market Forecasts by Region: Market Size ($bn), 2018, 2020, 2024, and 2029

COMPANIES LISTED:

  • AbbVie
  • Abramson Cancer Center
  • Admune Therapeutics
  • Aduro Biotech
  • Advaxis, Inc.
  • Agenus Inc.
  • Agilent Technologies
  • Alcon
  • Amgen
  • Amplimmune
  • AnaptysBio
  • Apexigen, Inc.
  • AREVA Med
  • ARIAD Pharmaceuticals, Inc.
  • Array BioPharma
  • AstraZeneca
  • Aurigene Discovery Technologies
  • Basilea Pharmaceutica Ltd.
  • BeiGene
  • Bristol-Myers Squibb
  • Calithera Biosciences Inc.
  • cCAM Biotherapeutics
  • Celgene
  • Celldex Therapeutics Inc.
  • Chugai
  • Clal Biotech
  • Clovis Oncology, Inc.
  • CoStim Pharmaceuticals
  • CureTech, Ltd.
  • Curis, Inc.
  • Daiichi Sankyo Company, Limited
  • Dako
  • DNAtrix
  • Dynavax
  • Eddingpharm
  • Eisai Co., Ltd.
  • Eli Lilly
  • Exelixis, Inc.
  • GE Healthcare
  • GeneCentric Diagnostics, Inc.
  • Heptares Therapeutics
  • IBM
  • Immune Design
  • Immunocore Limited
  • Immutep
  • Incyte
  • Innate Pharma
  • Inovio Pharmaceuticals
  • IOmet Pharma Ltd.
  • Janssen Biotech, Inc.
  • Kolltan Pharmaceuticals, Inc.
  • Kyowa Hakko Kirin
  • MacroGenicS Inc.
  • Medarex
  • MedImmune
  • Medivation, Inc
  • Merck & Co.
  • Merus N.V.
  • Moderna Therapeutics
  • Moffitt Cancer Center
  • MS
  • NanoString Technologies, Inc.
  • NEC Corporation
  • NewLink Genetics
  • Novartis
  • Oncothyreon Inc.
  • Ono Pharmaceutical
  • Peregrine Pharmaceuticals
  • Pfizer, Inc.
  • Plexxikon Inc.
  • Prima Biomed
  • Regeneron Pharmaceuticals
  • Roche
  • Sandoz
  • Sanofi
  • Seattle Genetics, Inc.
  • Sosei Group Corporation
  • Surface Oncology
  • Syndax Pharmaceuticals
  • Syros Pharmaceuticals, Inc.
  • TARIS Biomedical LLC
  • TESARO, Inc.
  • TetraLogic Pharmaceuticals Corporation
  • Transgene SA
  • Western Oncolytics
  • Xencor

List of Organisations Mentioned in the Report:

  • Cancer Research Institute
  • Central Social Insurance Medical Council
  • Data Monitoring Committee
  • Early Access to Medicines Scheme
  • European Cancer Congress
  • European Medicines Agency
  • European Organisation for Research and Treatment of Cancer
  • MD Anderson Cancer Center
  • Medicines and Healthcare Products Regulatory Agency
  • Ministry of Health, Labour, and Welfare
  • National Cancer Institute
  • National Institute for Health and Clinical Excellence
  • QIMR Berghofer Medical Research Institute
  • University of Pittsburgh
  • Yamaguchi University
目次
Product Code: PHA0423

The global checkpoint inhibitors for anti-cancer treatment market is estimated to have reached $11.43 bn in 2018 and is expected to grow at a CAGR of 13.7% during the forecast period.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 152-page report you will receive 72 tables and 32 figures - all unavailable elsewhere.

The 152-page report provides clear detailed insight into the global checkpoint inhibitors for anti-cancer treatment market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

Global Checkpoint Inhibitors Anti-Cancer Treatment Market forecasts from 2018-2029

Global Checkpoint Inhibitors Anti-Cancer Treatment Market forecasts from 2018-2029 by Leading Drugs:

  • Yervoy (ipilimumab)
  • Opdivo (nivolumab)
  • Keytruda (pembrolizumab)

Global Checkpoint Inhibitors Anti-Cancer Treatment Market forecasts from 2018-2029 by Class:

  • CTLA-4 Inhibitors
  • PD-1 Inhibitors
  • Pipeline Drugs

Checkpoint Inhibitors Anti-Cancer Treatment Market forecasts from 2018-2029 by regional and national market:

  • U.S.
  • EU: Germany, France, Italy, U.K., Spain
  • Japan
  • APAC

Profiles of the selected leading companies:

  • AstraZeneca, Plc
  • Bristol-Myers Squibb Co.
  • Celldex Therapeutics, Inc.
  • Incyte Corporation
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Roche Holding AG
  • The Checkpoint Inhibitors Anti-Cancer Treatment Market Pipeline Analysis
  • A SWOT analysis of the global checkpoint inhibitors anti-cancer treatment market

Key Questions Answered by this Report:

  • What are the global revenue prospects for the period 2018 to 2029?
  • What are the leading national market potentials from 2018 to 2029?
  • How is the checkpoint inhibitor anti-cancer treatment drugs market evolving?
  • What is driving and restraining the checkpoint inhibitor anti-cancer treatment drugs market?
  • What are the market shares of each segment of the overall checkpoint inhibitor anti-cancer treatment drugs market?
  • How will main checkpoint inhibitor anti-cancer treatment submarket segments develop over the forecast period and how much revenue will these submarkets account for in 2029?
  • How will the market shares for each checkpoint inhibitor anti-cancer treatment submarket develop from 2018 to 2029?
  • Which therapies can succeed and what revenues could they generate to 2029?
  • What will be the main commercial drivers for the market from 2018 to 2029?
  • How will market shares of prominent national markets change from 2018, and which countries will lead the market in 2029, achieving highest revenues and fastest growth?
  • How will that industry evolve between 2018 and 2029, especially in R&D?

Visiongain's study is intended for anyone requiring commercial analyses for the Global Checkpoint Inhibitors Anti-Cancer Treatment Drugs Market. You find data, trends and predictions.

Buy our report today Checkpoint Inhibitors for Anti-Cancer Treatment Market 2019-2029: CTLA-4 Inhibitors, PD-1 Inhibitors, 3 PD-L1 Inhibitors, Ipilimumab, Nivolumab, Pembrolizumab, Pipeline Drugs. ’

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1 Global Overview of the Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market 2018
  • 1.2 Benefits of This Report
  • 1.3 How This Report Delivers
  • 1.4 Key Questions Answered by This Analytical Report
  • 1.5 Who is This Report For?
  • 1.6 Methods of the Study
  • 1.7 Frequently Asked Questions (FAQ)
  • 1.8 Associated Visiongain Reports
  • 1.9 About Visiongain

2. Introduction to the Checkpoint Inhibitor Anti-Cancer Treatment Drugs World Market 2018

  • 2.1 Checkpoint Inhibitors: A New Era in Immunotherapy
  • 2.2 Checkpoint Inhibitor Treatment Drugs in Oncology
  • 2.3 Application Segment
    • 2.3.1 Lung Cancer
    • 2.3.2 Bladder Cancer
    • 2.3.3 Melanoma
    • 2.3.4 Hodgkin Lymphoma

3. Leading Checkpoint Inhibitors Anti-Cancer Treatment Drugs Market Forecasts 2019-2029 and Leading Companies in the World Market

  • 3.1 Leading Checkpoint Inhibitor Anti-Cancer Treatment Drugs in the Market 2019
    • 3.1.1 Yervoy (ipilimumab) - Bristol-Myers Squibb
      • 3.1.1.1 Yervoy: Sales Analysis
    • 3.1.2 Opdivo (nivolumab) - Bristol-Myers Squibb/Ono Pharmaceutical
      • 3.1.2.1 Opdivo: Sales Analysis
    • 3.1.3 Keytruda (pembrolizumab) - Merck & Co.
      • 3.1.3.1 Keytruda: Sales Analysis
  • 3.2 Leading Companies in the Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market in 2018
    • 3.2.1 Bristol-Myers Squibb Leads the Market

4. Checkpoint Inhibitor Anti-Cancer Treatment Drugs: World Market 2019-2029

  • 4.1 The Global Market for Checkpoint Inhibitor Anti-Cancer Treatments in 2018
  • 4.2 The World Checkpoint Inhibitors Anti-Cancer Treatment Drugs Market: Revenue Forecasts 2019-20
  • 4.3 Leading Checkpoint Inhibitor Anti-Cancer Treatment Drugs Submarkets Forecast 2019-2029
    • 4.3.1 The CTLA-4 Inhibitors Submarket Forecast 2019-2029
    • 4.3.2 The PD-1 Inhibitors Submarket Forecast 2019-2029
    • 4.3.3 Changing Market Shares: PD-1 Inhibitors Will Lead the Market
    • 4.3.4 Market Dynamics of the Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market 2019-2029
      • 4.3.4.1 Drivers of the Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market
      • 4.3.4.2 Restraints of the Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market
      • 4.3.4.3 Opportunity of the Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market
      • 4.3.4.4 Trends of the Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market

5. Leading National Markets for the Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market 2019-2029

  • 5.1 Epidemiology of Major Cancer types
    • 5.1.1 Lung Cancer
    • 5.1.2 Bladder Cancer
    • 5.1.3 Melanoma
    • 5.1.4 Hodgkin Lymphoma
    • 5.1.5 Pancreatic Cancer
  • 5.2 Regional Breakdown of the World Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market 2019-2029
  • 5.3 World Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Regional Forecast, 2019-2029
    • 5.3.1 How Will Regional Market Shares Change by 2029?
  • 5.4 The US Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market Forecast 2019-2029
  • 5.5 The EU Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market Forecast 2019-2029
    • 5.5.1 Germany: The Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market Forecast 2019-2029
    • 5.5.2 France: The Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market Forecast 2019-2029
    • 5.5.3 Italy: The Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market Forecast 2019-2029
    • 5.5.4 The UK: The Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market Forecast 2019-2029
    • 5.5.5 Spain: The Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market Forecast 2019-2029
  • 5.6 Japan: The Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market Forecast 2019-2029
  • 5.7 The APAC Market: Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market Forecast 2019-2029

6. The Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market Pipeline Analysis 2019-2029

  • 6.1 Anti-PD-1 Inhibitors and Anti-PD-L1 Inhibitors
    • 6.1.1 Tecentriq (Atezolizumab)
    • 6.1.2 Pidilizumab (CT-011) - CureTech, Ltd.
    • 6.1.3 AMP-224 - GSK/Amplimmune
    • 6.1.4 REGN2810 - Regeneron/Sanofi
    • 6.1.5 Libtayo
  • 6.2 CTLA-4 Inhibitors
    • 6.2.1 Tremelimumab (CP-675,206) - AstraZeneca
  • 6.3 LAG-3 (lymphocyte activation gene-3) Inhibitors
    • 6.3.1 IMP321- Prima Biomed
    • 6.3.2 BMS-986016 - Bristol-Myers Squibb
    • 6.3.3 IMP701 - Prima BioMed/Novartis
  • 6.4 KIR Inhibitors
    • 6.4.1 Lirilumab (IPH2102/BMS-986015) - Innate Pharma/Bristol-Myers Squibb
  • 6.5 Anti-NKG2A Inhibitors
    • 6.5.1 IPH2201 - Innate Pharma/AstraZeneca/MedImmune
  • 6.6 Other Checkpoint Inhibitors
    • 6.6.1 VISTA Inhibitors
      • 6.6.1.1 CA-170 - Curis Inc/Aurigene Discovery Technologies
      • 6.6.1.2 NLG919 - NewLink Genetics
      • 6.6.1.3 INCB024360 - Incyte/Roche
    • 6.6.2 A2aR Inhibitors
  • 6.6.2.1 HTL-1071 - AstraZeneca/Heptares
  • 6.7 Clinical trial landscape for Immune checkpoint inhibitors
  • 6.8 Clinical trial landscape for pd1/L1 Immune checkpoint inhibitors

7. Qualitative Analysis of the Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market 2019-2029

  • 7.1 SWOT Analysis of the Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market 2019-2029
    • 7.1.1 Strengths and Weaknesses of the Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market
      • 7.1.1.1 A Novel Treatment Method that Harnesses the Immune System's Vast Potential
      • 7.1.1.2 Pricing of the Treatments Will Attract Companies
      • 7.1.1.3 Cost of Treatment Will Restrain Market Access
      • 7.1.1.4 Side Effects May Prohibit Growth
    • 7.1.2 Opportunities and Threats for the Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market
      • 7.1.2.1 Biomarkers Pave the Way for Optimum Utility
      • 7.1.2.2 Combination Therapies are Achieving Superior Results
      • 7.1.2.3 The Cost Burden of Expensive Drug Treatments on Healthcare Systems
      • 7.1.2.4 Crowding of the Market with Similar Products

8. Company Profiles

  • 8.1 AstraZeneca Plc.
    • 8.1.1 Company Overview
    • 8.1.2 Key Developments
  • 8.2 Bristol-Myers Squibb Co.
    • 8.2.1 Company Overview
    • 8.2.2 Key Developments
  • 8.3 Celldex Therapeutics Inc.
    • 8.3.1 Company Overview
    • 8.3.2 Key Developments
  • 8.4 Incyte Corporation
    • 8.4.1 Company Overview
    • 8.4.2 Key Developments
  • 8.5 Merck & Co., Inc.
    • 8.5.1 Company Overview
    • 8.5.2 Key Developments
  • 8.6 Novartis Ag
    • 8.6.1 Company Overview
    • 8.6.2 Key Developments
  • 8.7 Pfizer Inc.
    • 8.7.1 Company Overview
    • 8.7.2 Key Developments
  • 8.8 Roche Holding Ag
    • 8.8.1 Company Overview
    • 8.8.2 Key Developments

9. Conclusions

  • 9.1 The Global Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market: Current World Outlook
    • 9.1.1 Driver for Growth: A Robust and Innovative Pipeline for the Checkpoint Inhibitors Anti-Cancer Treatment Drugs Market to 2029
  • 9.2 Leading National Markets for the Checkpoint Inhibitor Anti-Cancer Treatment Market 2019-2029: The US and EU Will Retain Their Lead
  • 9.3 The Future of the Checkpoint Inhibitor Anti-Cancer Treatment Drugs Market

Appendices

  • Associated Visiongain Reports
  • Visiongain Report Sales Order Form
  • About Visiongain
  • Visiongain report evaluation form